Skip to main content
OpenTrials
Completed

NCT Number: NCT02897778

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms Breast Diseases Breast Neoplasms Bronchial Diseases Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Lung Diseases Lung Neoplasms Male Urogenital Diseases Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Renal Neoplasm Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin and Connective Tissue Diseases Solid Tumors Thoracic Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

The START Center for Cancer Care

San Antonio, Texas, 78229, United States

About this study

This is a single center, randomized, placebo-controlled, single dosing schedule, double-blinded study to evaluate the effect of entinostat as compared to placebo on the electrical activity of the heart in patients with advanced solid tumors. Thirty patients will be randomized in a 1:1 ratio to receive either entinostat or placebo. Study treatment will be blinded to patients and the Investigator. ECG analysts will be blinded to the patient, visit, and treatment allocation. Patients will be on study up to 30 days following study drug administration. Total study duration is expected to be 9 months. After completing this study and at the discretion of the Investigator, patients may elect to enroll into a separate continuation study (SNDX-275-0141).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically or cytologically confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapy(ies) or for which there is no approved therapy
  • Patients must have acceptable laboratory requirements
  • Left ventricular ejection fraction as measured by echocardiogram or multiple-gated acquisition scan that is above the institutional lower level of normal or greater than 50%
  • Has experienced resolution of toxic effect(s) of the most recent prior chemotherapy and/or prior surgical and radiation treatment
  • Must be able to understand and give written informed consent and comply with study procedures

Exclusion criteria

  • If the patient has brain metastasis, they must have stable neurologic status without the use of steroids or on a stable or decreasing dose of steroids
  • Presence of clinically significant gastrointestinal abnormalities that may affect the absorption of study treatments
  • A medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the Investigator
  • Patient has a concomitant cardiovascular issue that precludes adequate study treatment compliance or increases patient risk
  • Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
  • Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study
  • Prior anti-cancer monoclonal antibody within 4 weeks prior to baseline
  • Currently enrolled in another investigational study
  • Has disease that is suitable for approved therapy administered with curative intent

Treatment and study plan

Entinostat

Drug

Single, supratherapeutic dose of entinostat given orally.

Other names: SNDX-275, MS-275

Placebo

Drug

Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).

Primary outcomes

  1. Change from Baseline in Heart Rate (HR)

    Time frame: Baseline (pre-dose) through 24 hours post-dose

    Heart rate measured in beats per minute (bpm).

  2. Change from Baseline in Electrocardiogram Procedures

    Time frame: Baseline (pre-dose) through 24 hours post-dose

    Change from baseline in QT interval corrected for heart rate (Qtc), PR interval (PR) and QRS complex (QRS).

  3. Change from Baseline in T-Cell Morphology

    Time frame: Baseline (pre-dose) through 24 hours post-dose

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)

    Time frame: First dose through 30 days post-dose or through resolution of acute toxicities (Up to 31 days)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A TEAE is an AE that occurs after the first dose of study drug. A SAE is defined as any AE that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.

  2. Number of Participants with Clinically Significant Abnormalities in Laboratory Values Reported as a TEAE

    Time frame: Baseline (pre-dose) through 14 days post-dose or 30 day safety follow-up visit (if applicable)

    Standard safety laboratory tests included Chemistry, Hematology. Any hematologic or clinical chemistry abnormality considered by the investigator to be clinically significant was reported as a TEAE.

  3. Change from Baseline in Vital Signs

    Time frame: Baseline (pre-dose) through 14 days post-dose or 30 day safety follow-up visit (if applicable)

    Vital signs included temperature, pulse, blood pressure, and respiration rate

  4. Change from Baseline in ECG Values

    Time frame: Baseline ()pre-dose through 14 days post-dose or 30 day safety follow-up visit (if applicable)

    A 12-lead continuous ECG recording (via a Holter) was recorded on Day 1 for 25 hours. Safety ECGs were read and interpreted by the Investigator on-site for the purpose of safety monitoring and were transmitted electronically to the central ECG laboratory for clinical interpretation by a cardiologist

  5. Change from Baseline in QTc

    Time frame: Pre-dose through 24 hours post-dose

  6. Cmax (Maximum Plasma Concentration) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

  7. Tmax (Time of Maximum Plasma Concentration) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

  8. AUC0-24 (Area under the Plasma Concentration-time Curve from Time Zero to 24 hours) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

  9. AUC0-t (Area under the Plasma Concentration-time Curve from Time Zero to the Last Measurable Concentration) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

  10. AUC0-inf (Area under the Plasma Concentration-time Curve from 0-time Extrapolated to Infinity) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

  11. t1/2 (Elimination Half-life and Apparent Plasma Terminal Phase Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

  12. λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose

    Time frame: Pre-dose and multiple time-points through 24 hours post-dose and 14 days post-dose

Other outcomes

  1. Changes in Immune Regulatory Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose, Relative to Placebo Control

    Time frame: Pre-dose through 14 days post-dose

  2. Variability and Changes in Protein Lysine Acetylation in Peripheral Blood Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose and Examine the Underlying Biological Variation

    Time frame: Pre-dose through 14 days post-dose

Sponsors and collaborators

Lead sponsor

Syndax Pharmaceuticals

Industry

Registry information

Official study title

A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Sep 13, 2016
Registry last updated
Apr 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.